Best selling report

Personalized Medicine Partnering Terms and Agreements

The Personalized Medicine Partnering Terms & Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies..... More

Featured partnering deals

Probi signs a pharma deal with big pharma Sanofi

April 16, 2014 : big pharma, partnering, pharma deals, Sanofi

Probi has signed a pharma deal for distribution and supply with Sanofi for Digestis. more »

Aveo and Biodesix sign a pharma alliance for companion diagnostic test

April 15, 2014 : biotech, companion diagnostic, diagnostic, pharma deals

AVEO Oncology and Biodesix entered into a worldwide pharma alliance to develop and commercialize AVEO’s hepatocyte growth factor inhibitory antibody ficlatuzumab, with a Biodesix companion diagnostic test. more »

 More partnering deals


Featured M&A deals

Mallinckrodt scoops up Questcor in a m&a deal

April 8, 2014 : acquisition, big biotech, big pharma, biotech, M&A

Mallinckrodt and Questcor Pharmaceuticals have entered into a definitive m&a agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion. more »

Sun Pharma and Ranbaxy engage in M&A transaction

April 7, 2014 : acquisition, Daiichi Sankyo, M&A, Ranbaxy

Sun Pharmaceutical agreed to m&a transaction to buy competitor Ranbaxy Laboratories for $3.2 billion from Japan’s Daiichi Sankyo, which paid 61 percent more for the company five years ago. more »

 More M&A deals

Featured financing deals

Nexvet closes $31.5 million in financing

April 17, 2014 : financing, financings

Nexvet Biopharma announced the closing of its US$31.5 million Series B round of financing. more »

Epirus gets $36 million in Series B financing

April 17, 2014 : financing, financings

Epirus also announced today that it has closed a $36 million Series B financing round led by Livzon Mabpharm, Inc. more »

 More financing deals

Latest Dealtalk

Meda rejects Mylan M&A approach

April 7, 2014 : dealtalk, M&A

Swedish generic drugmaker Meda AB rejected a M&A approach by U.S. rival Mylan Inc to create a combined company worth around $24 billion. more »

Smith & Nephew recommended for 3-way split

March 31, 2014 : dealtalk

Smith & Nephew  is suggested to split itself in 3-way by  Investec. more »

 More dealtalk

Featured reports

Companion Diagnostics Partnering Terms and Agreements

Publication date: April 2014

Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Publication date: April 2014

Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Publication date: April 2014

Biomarker Partnering Terms and Agreements

Publication date: April 2014

Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Publication date: April 2014

Orphan Diseases Partnering Terms and Agreements

Publication date: April 2014

Partnering Deals and Alliances with Big Pharma

Publication date: March 2014

Regenerative Medicine and Stem Cells Partnering Terms and Agreements

Publication date: March 2014

 

NEW: Therapy deal reports covering all major indications

Including partnering in oncology, cardiovascular, CNS, metabolic, dermatology, dental, infectives, immunologypsychiatry, genitourinary.....plus many others

View all reports

Scorecard

Current Partnering provides access to key deal metrics for all leading partnering, M&A and financings - plus big pharma partnering activity and R&D spend metrics.

Available scorecards:

Partnering

M&A

Financing

Top 50 pharma partnering

Top 50 biotech partnering

Top pharma R&D spend

Deal metrics - by stage of development, therapy area, industry sector

Print Friendly
ca300x150gif
RSS Feed Linked In Twitter

Latest Tweets

cp300x1502gif
nlsd2014jpg
biotech-china-300-x150newjpg